Arena Investors: You Need More Than a Blockbuster

Before you go, we thought you'd like these...
Before you go close icon

Arena Pharmaceuticals and VIVUS  are the epitome of water-cooler stocks. Every American knows that our country is dealing with an obesity epidemic, so what could be more of a "sure thing" stock than companies behind weight management pills that are clinically proven to work? If it sounds to good to be true, it's because it is.

In the following video, health care bureau chief Brenton Flynn provides a brief overview for those who are new to the Arena Pharmaceuticals story. Specifically, he discusses why a partnership that Arena entered into means that its drug, Belviq, needs to become much more than a blockbuster drug to provide shareholders with the profits they're looking for.


Are there any reasons left to own Arena?
With Belviq's FDA approval now a distant memory, investors are scrambling to decide whether to buy or sell Arena. In the Fool's premium research report, senior biotech analyst Brian Orelli takes you through a comprehensive look at this contentious stock, including its massive opportunity, potential pitfalls, and key reasons to both buy and sell. To find out more about Arena -- and get a full year of updates -- click here to access your report today.

The article Arena Investors: You Need More Than a Blockbuster originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners